- Home
- SABR vs NRIX Comparison
SABR vs NRIX Comparison
Compare SABR & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABR
- NRIX
- Stock Information
- Founded
- SABR 2006
- NRIX 2009
- Country
- SABR United States
- NRIX United States
- Employees
- SABR N/A
- NRIX N/A
- Industry
- SABR Computer Software: Programming Data Processing
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- SABR Technology
- NRIX Health Care
- Exchange
- SABR Nasdaq
- NRIX Nasdaq
- Market Cap
- SABR 1.3B
- NRIX 1.4B
- IPO Year
- SABR 2014
- NRIX 2020
- Fundamental
- Price
- SABR $3.34
- NRIX $19.14
- Analyst Decision
- SABR Hold
- NRIX Strong Buy
- Analyst Count
- SABR 4
- NRIX 17
- Target Price
- SABR $3.50
- NRIX $30.29
- AVG Volume (30 Days)
- SABR 3.7M
- NRIX 832.5K
- Earning Date
- SABR 02-13-2025
- NRIX 02-13-2025
- Dividend Yield
- SABR N/A
- NRIX N/A
- EPS Growth
- SABR N/A
- NRIX N/A
- EPS
- SABR N/A
- NRIX N/A
- Revenue
- SABR $3,001,894,000.00
- NRIX $56,424,000.00
- Revenue This Year
- SABR $6.30
- NRIX N/A
- Revenue Next Year
- SABR $5.01
- NRIX $3.79
- P/E Ratio
- SABR N/A
- NRIX N/A
- Revenue Growth
- SABR 5.26
- NRIX N/A
- 52 Week Low
- SABR $1.81
- NRIX $7.65
- 52 Week High
- SABR $4.60
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- SABR 40.04
- NRIX 45.09
- Support Level
- SABR $3.19
- NRIX $17.50
- Resistance Level
- SABR $3.42
- NRIX $20.50
- Average True Range (ATR)
- SABR 0.11
- NRIX 1.12
- MACD
- SABR -0.03
- NRIX 0.16
- Stochastic Oscillator
- SABR 27.27
- NRIX 54.67
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2023 revenue, split between distribution (78% of segment sales) and airline IT solutions (22%) revenue. The company also has a growing hotel IT solutions division (9% of revenue). Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.